Cargando…

GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells

OBJECTIVE: GW4869 is an exosomal inhibitor. It is necessary to delay the occurrence of gefitinib resistance during non-small-cell lung cancer (NSCLC) treatment. This study aimed to investigate the anti-tumor effects of GW4869 on epithelial-mesenchymal transition (EMT) and expression of extracellular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wan, Xuan, Fang, Yuting, Du, Jiangzhou, Cai, Shaoxi, Dong, Hangming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640835/ https://www.ncbi.nlm.nih.gov/pubmed/38021444 http://dx.doi.org/10.2147/OTT.S428707

Ejemplares similares

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
por: Hu, Yong, et al.
Publicado: (2017)

Blockade of exosome generation by GW4869 inhibits the education of M2 macrophages in prostate cancer
por: Peng, Yilin, et al.
Publicado: (2022)

The Promotional Effect of GW4869 on C. albicans Invasion and Cellular Damage in a Murine Model of Oral Candidiasis
por: Zhang, Miaomiao, et al.
Publicado: (2022)

The role of secreted Hsp90α in HDM-induced asthmatic airway epithelial barrier dysfunction
por: Ye, Cuiping, et al.
Publicado: (2019)

Zika virus propagation and release in human fetal astrocytes can be suppressed by neutral sphingomyelinase-2 inhibitor GW4869
por: Huang, Yunlong, et al.
Publicado: (2018)

nSMase2 (Type 2-Neutral Sphingomyelinase) Deficiency or Inhibition by GW4869 Reduces Inflammation and Atherosclerosis in Apoe(−/−) Mice
por: Lallemand, Tom, et al.
Publicado: (2018)

Extracellular HSP90α Interacts With ER Stress to Promote Fibroblasts Activation Through PI3K/AKT Pathway in Pulmonary Fibrosis
por: Zhang, Jinming, et al.
Publicado: (2021)

Inhibition of GPR30 sensitized gefitinib to NSCLC cells via regulation of epithelial-mesenchymal transition
por: Yang, Xiaomin, et al.
Publicado: (2023)

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

Transient HSP90 inhibition enhances the sensitivity of mantle cell lymphoma to poly (ADP-ribose) polymerase (PARP) inhibitors
por: Shi, Chaowen, et al.
Publicado: (2023)

Extracellular HSP70/HSP70-PCs Promote Epithelial-Mesenchymal Transition of Hepatocarcinoma Cells
por: Li, Hangyu, et al.
Publicado: (2013)

HIV in Europe and Central Asia: progress in 2018 towards meeting the UNAIDS 90-90-90 targets
por: Brown, Alison E, et al.
Publicado: (2018)

Extracellular Hsp90α, which participates in vascular inflammation, is a novel serum predictor of atherosclerosis in type 2 diabetes
por: Ding, Xinyi, et al.
Publicado: (2022)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

HSP90AA1 promotes lymphatic metastasis of hypopharyngeal squamous cell carcinoma by regulating epithelial-mesenchymal transition
por: TANG, FENGXIANG, et al.
Publicado: (2023)

Effects of TGF-β1 Receptor Inhibitor GW788388 on the Epithelial to Mesenchymal Transition of Peritoneal Mesothelial Cells
por: Lho, Yunmee, et al.
Publicado: (2021)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

HSP70 and HSP90 Differentially Regulate Translocation of Extracellular Antigen to the Cytosol for Cross-Presentation
por: Kato, Yu, et al.
Publicado: (2012)

Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90
por: Zhang, Guohua, et al.
Publicado: (2017)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
por: Ueda, Yasunori, et al.
Publicado: (2017)

Extracellular Heat Shock Protein-90 (eHsp90): Everything You Need to Know
por: Jay, Daniel, et al.
Publicado: (2022)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
por: Lin, Chien-Chung, et al.
Publicado: (2021)

Breast Cancer MDA-MB-231 Cells Use Secreted Heat Shock Protein-90alpha (Hsp90α) to Survive a Hostile Hypoxic Environment
por: Dong, Hangming, et al.
Publicado: (2016)

Targeting extracellular Hsp90: A unique frontier against cancer
por: Sager, Rebecca A., et al.
Publicado: (2022)

Mesenchymal stromal cell-derived small extracellular vesicles modulate macrophage polarization and enhance angio-osteogenesis to promote bone healing
por: Chuah, Shang Jiunn, et al.
Publicado: (2021)

Triptolide inhibits epithelial-mesenchymal transition and induces apoptosis in gefitinib-resistant lung cancer cells
por: Li, Fangqiong, et al.
Publicado: (2020)

Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
por: Salem, Riad, et al.
Publicado: (2021)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

PNSA, a Novel C-Terminal Inhibitor of HSP90, Reverses Epithelial–Mesenchymal Transition and Suppresses Metastasis of Breast Cancer Cells In Vitro
por: Zhang, Aotong, et al.
Publicado: (2021)

The Therapeutic Roles of Recombinant Hsp90α on Cornea Epithelial Injury
por: Wang, Mingli, et al.
Publicado: (2022)

Regulation of TGF-β-mediated endothelial-mesenchymal transition by microRNA-27
por: Suzuki, Hiroshi I., et al.
Publicado: (2017)

GW Stewart
por: Kilmer, Misha E, et al.
Publicado: (2010)

Genome-wide identification and expression analysis of the Hsp20, Hsp70 and Hsp90 gene family in Dendrobium officinale
por: Wang, Hongman, et al.
Publicado: (2022)

Extracellular HSP90 Machineries Build Tumor Microenvironment and Boost Cancer Progression
por: Poggio, Pietro, et al.
Publicado: (2021)

Circulating heat shock protein 90 (Hsp90) and autoantibodies to Hsp90 are increased in patients with atopic dermatitis
por: Sitko, Krzysztof, et al.
Publicado: (2021)

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro
por: Hu, Yong, et al.
Publicado: (2017)

Author Correction: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
por: Wang, Yue-qin, et al.
Publicado: (2020)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016)

Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and Hsp90 Inhibitors
por: Naz, Shuguftha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qe2tja0v1gmhuqku7jr6e003om